101101
Fatores de risco modificáveis: tabagismo, sedentarismo, obesidade, síndrome metabólica,
dislipidémia, hipertensão arterial, diabetes e fatores psicossociais
32. Gylling H, Plat J, Turley S, et al. European Atherosclerosis Society consensus Panel on Phyto-
sterols. Plant sterols and plant stanols in the management of dislipidemia and prevention of
cardiovascular disease. Atherosclerosis. 2014; 232: 346-360.
33. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guidelines for the management
of High Blood Pressure in adults: Report from the Eight Joint National Committee (JNC 8).
JAMA. 2014; 311: 507-520.
34. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of
arterial hypertension. Eur Heart J. 2013; 34: 2159–2219.
35. O’Donnell M, Mente A, Yusuf S. Sodium intake and cardiovascular health. Circ Res. 2015;
116: 1046-1057.
36. Fagard RH, Bjornstad HH, Borjessen M, et al. ESC study group of sports cardiology recom-
mendations for participation on leisure-time physical activities and competition sports for
patients with hypertension. Eur J Cardiovasc Prev Rehab. 2005; 12: 326-339.
37. Ruivo JA, Alcântara P. Hypertension and exercise. Rev Port Cardiol. 2012; 31: 151-158.
38. Pescatello LS, Franklin BA, Fagard R, et al. Exercise and hypertension. American College of
Sports Medicine Position stand. Med Sci Sports Exercise. 2004; 36: 533-553.
39. Sosner P, Gremeaux V, Bosquet L, et al. High blood pressure and physical activity. Ann Card
Angeiol. 2014, 63: 197-203.
40. Rosendorff C, Lackland DT, Allison M, et al. Treatment of Hypertension in patients with
coronary artery disease: A scientific statement from the American Heart Association, Ame-
rican College of Cardiology, and American Society of Hypertension. J Am Soc Hypert. 2015;
9: 453-498.
41. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur
Heart J. 2011; 32: 2499-2506.
42. IDF Diabetes atlas 6
th
ed 2013. International Diabetes Federation. P11-12.
43. Diabetes: factos e números 2014 – relatório anual do observatório nacional de diabetes.
Lisboa. Sociedade Portuguesa Diabetologia. 2014; P8.
44. Fox CS, Golden SH, Anderson C, et al. Update on Prevention of Cardiovascular Disease in
Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement
From the American Heart Association and the American Diabetes Association. Diabetes
Care. 2015; 38:1777-803.
45. Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes
mellitus: implications of recent clinical trials. Am Intern Med. 2011; 154: 554-559.
46. Bailey CJ.The Current Drug Treatment Landscape for Diabetes and Perspectives for the
Future. Clin Pharmacol Ther. 2015; 98:170-84.
47. Alvarez CA, Lingvay I, Vuylsteke V, et al.. Cardiovascular Risk in Diabetes Mellitus: Com-
plication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther 2015;
98:145-61.
48. Monami M, Genovese S, Mannuci E. Cardiovascular safety of sulfonylureas: a meta-analysis of
randomised clinical trials. Diabetes Obes Metab. 2013; 15: 938-953.
